ReproCELL Incorporated (4978) Q3 2025 earnings summary

Executive summary

• Revenue for the nine months ended December 31, 2024, was ¥2,068 million, up 16.4% year-over-year; operating loss narrowed to ¥180 million from ¥289 million; net loss attributable to shareholders was ¥31 million, compared to a profit of ¥48 million in the prior year.

• Research support and medical businesses both contributed to growth, with the research support segment as the main revenue driver and the medical segment focused on regenerative medicine and clinical trials.

Financial highlights

• Revenue increased to ¥2,068 million (up 16.4% year-over-year); operating loss improved to ¥180 million; ordinary loss was ¥33 million; net loss attributable to shareholders was ¥31 million.

• Comprehensive loss for the period was ¥98 million, compared to a comprehensive income of ¥152 million in the prior year.

• Total assets rose to ¥11,233 million from ¥9,052 million at the previous fiscal year-end; net assets increased to ¥8,893 million.

• No dividends were paid or planned for the period.

Outlook and guidance

• Full-year revenue forecast remains at ¥2,661 million (up 9.7% year-over-year); operating loss projected at ¥325 million; net loss forecast at ¥174 million.

• No changes to previously announced guidance.